Previous 10 | Next 10 |
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson’s 13F stock portfolio on a quarterly basis. It is based on Paulson’s regulatory 13F Form filed on 11/14/2019. Please visit our Tracking John Paulson’s Paulson & Co...
Source: Bloomberg Generic drug manufacturers like Mylan ( MYL ) have been reeling from declining revenue. Large corporations are using their leverage to negotiate lower prices for generics. The FDA is approving drugs faster, which is creating more competition and falling revenue. Mylan may...
HERTFORDSHIRE, England and PITTSBURGH , Nov. 25, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will present at the Evercore ISI HealthCONx Conference in Boston on Tuesday, Dec. 3, 2019 at 11 a.m. ET . Interested parties...
The Wall Street Journal reports that less than 2/3 (n=1,249) of generic drugs approved in the U.S. between 2016 - 2018 are on the market. Only 30% (n=134/442) of the medicines approved last year have gone on sale. More news on: Health Care Select Sect SPDR ETF, SPDR Biotech ETF, Invesco ...
The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Mylan N.V.'s (NASDAQ: MYL ) clopidogrel/acetylsalicylic acid, a generic version of Sanofi's (NASDAQ: SNY ) heart med DuoPlavin. More news on: Mylan N.V., Sanofi, Healthcare st...
The FDA has sent a Warning Letter to Mylan N.V. ( MYL -1.1% ) concerning "significant deviations" from good manufacturing practice for active pharmaceutical ingredients (API) at its Unit 8 facility in Vizianagaram, Andhra Pradesh, India. More news on: Mylan N.V., Healthcare stocks...
I've been using a modified version of David Van Knapp 's quality scoring system to rank the Dividend Aristocrats , the Dividend Kings , and the Dividend Champions . The system employs five widely used quality indicators from independent sources and assigns 0-5 points to each quality indi...
The planned combination of Pfizer's ( PFE +0.2% ) Upjohn unit and Mylan N.V. ( MYL +2.8% ) will be named Viatris, the companies announce . More news on: Pfizer Inc., Mylan N.V., Healthcare stocks news, Merger & acquisition news, Stocks on the move, Read more ...
HERTFORDSHIRE, England , PITTSBURGH and NEW YORK , Nov. 12, 2019 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be Viatris (pro...
The following slide deck was published by Mylan N.V. in conjunction with their 2019 Q3 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
Mylan Announces Third Quarter 2020 Financial Results and Looks Ahead to the Launch of Viatris Inc. PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Nov. 6, 2020 HERTFORDSHIRE, England and PITTSBURGH , Nov. 6, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ...
Our experts issued a rare "Double Down" Buy alert on this one stock... Learn more. A long-awaited deal will soon be done. Pfizer (NYSE: PFE) and Mylan (NASDAQ: MYL) announced last week that the U.S. Federal Trade Commission has approved the planned merger of Pfizer's...
Mylan Announces Appointment of Experienced Pharmaceutical Executive Bill Szablewski as Head of Capital Markets for Viatris PR Newswire HERTFORDSHIRE, England, and PITTSBURGH, Nov. 2, 2020 HERTFORDSHIRE , England, and PITTSBURGH, Nov. 2, 2020 /PRNews...